279 related articles for article (PubMed ID: 18675552)
1. Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; Hoefgen ER; Swan JA; Colliver JA
Cytokine; 2008 Oct; 44(1):26-32. PubMed ID: 18675552
[TBL] [Abstract][Full Text] [Related]
2. Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome.
Fühlhuber V; Bick S; Kirsten A; Hahn A; Gerriets T; Tschernatsch M; Kaps M; Preissner KT; Blaes F; Altenkämper S
J Neuroimmunol; 2009 May; 210(1-2):87-91. PubMed ID: 19339060
[TBL] [Abstract][Full Text] [Related]
3. CCR7 signaling in pediatric opsoclonus-myoclonus: upregulated serum CCL21 expression is steroid-responsive.
Pranzatelli MR; Tate ED; McGee NR; Ransohoff RM
Cytokine; 2013 Oct; 64(1):331-6. PubMed ID: 23764550
[TBL] [Abstract][Full Text] [Related]
4. BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy.
Pranzatelli MR; Tate ED; McGee NR; Travelstead AL; Colliver JA; Ness JM; Ransohoff RM
J Neuroinflammation; 2013 Jan; 10():10. PubMed ID: 23324534
[TBL] [Abstract][Full Text] [Related]
5. Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS.
Pranzatelli MR; Tate ED; McGee NR; Travelstead AL; Ransohoff RM; Ness JM; Colliver JA
J Neuroimmunol; 2012 Feb; 243(1-2):81-8. PubMed ID: 22264765
[TBL] [Abstract][Full Text] [Related]
6. CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders.
Pranzatelli MR; Tate ED; McGee NR; Verhulst SJ
J Neuroimmunol; 2014 Jan; 266(1-2):75-81. PubMed ID: 24342231
[TBL] [Abstract][Full Text] [Related]
7. Elevated B cell-activating factor of the tumour necrosis factor family in coeliac disease.
Fabris M; Visentini D; De Re V; Picierno A; Maieron R; Cannizzaro R; Villalta D; Curcio F; De Vita S; Tonutti E
Scand J Gastroenterol; 2007 Dec; 42(12):1434-9. PubMed ID: 17852877
[TBL] [Abstract][Full Text] [Related]
8. Effect of low-dose cyclophosphamide, ACTH, and IVIG combination immunotherapy on neuroinflammation in pediatric-onset OMS: A retrospective pilot study.
Pranzatelli MR; Allison TJ; Tate ED
Eur J Paediatr Neurol; 2018 Jul; 22(4):586-594. PubMed ID: 29555260
[TBL] [Abstract][Full Text] [Related]
9. Expression of CXCR3 and its ligands CXCL9, -10 and -11 in paediatric opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; McGee NR; Travelstead AL; Verhulst SJ; Ransohoff RM
Clin Exp Immunol; 2013 Jun; 172(3):427-36. PubMed ID: 23600831
[TBL] [Abstract][Full Text] [Related]
10. Role of BAFF in Opsoclonus-Myoclonus syndrome, a bridge between cancer and autoimmunity.
Raffaghello L; Fuhlhuber V; Bianchi G; Conte M; Blaes F; Gambini C; Pistoia V
J Leukoc Biol; 2013 Jul; 94(1):183-91. PubMed ID: 23610147
[TBL] [Abstract][Full Text] [Related]
11. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; Travelstead AL; Barbosa J; Bergamini RA; Civitello L; Franz DN; Greffe BS; Hanson RD; Hurwitz CA; Kalinyak KA; Kelfer H; Khakoo Y; Mantovani JF; Nicholson SH; Sanders JM; Wegner S
J Pediatr Hematol Oncol; 2006 Sep; 28(9):585-93. PubMed ID: 17006265
[TBL] [Abstract][Full Text] [Related]
12. B cell depletion therapy for new-onset opsoclonus-myoclonus.
Pranzatelli MR; Tate ED; Swan JA; Travelstead AL; Colliver JA; Verhulst SJ; Crosley CJ; Graf WD; Joseph SA; Kelfer HM; Raju GP
Mov Disord; 2010 Jan; 25(2):238-42. PubMed ID: 20063398
[TBL] [Abstract][Full Text] [Related]
13. Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED
Brain Dev; 2016 May; 38(5):439-48. PubMed ID: 26786246
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid ACTH and cortisol in opsoclonus-myoclonus: effect of therapy.
Pranzatelli MR; Chun KY; Moxness M; Tate ED; Allison TJ
Pediatr Neurol; 2005 Aug; 33(2):121-6. PubMed ID: 16087057
[TBL] [Abstract][Full Text] [Related]
15. Cytokines, cytokine antagonists, and soluble adhesion molecules in pediatric OMS and other neuroinflammatory disorders.
Pranzatelli MR; Tate ED; McGee NR; Colliver JA
J Neurol Sci; 2013 Mar; 326(1-2):53-8. PubMed ID: 23380454
[TBL] [Abstract][Full Text] [Related]
16. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies.
Krystufková O; Vallerskog T; Helmers SB; Mann H; Putová I; Belácek J; Malmström V; Trollmo C; Vencovsky J; Lundberg IE
Ann Rheum Dis; 2009 Jun; 68(6):836-43. PubMed ID: 18628284
[TBL] [Abstract][Full Text] [Related]
17. [Opsoclonus myoclonus ataxia syndrome in Israel].
Blumkin L; Lerman-Sagie T
Harefuah; 2010 Jan; 149(1):24-8, 63. PubMed ID: 20422836
[TBL] [Abstract][Full Text] [Related]
18. Chemokine/cytokine profiling after rituximab: reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS.
Pranzatelli MR; Tate ED; Travelstead AL; Verhulst SJ
Cytokine; 2011 Mar; 53(3):384-9. PubMed ID: 21211990
[TBL] [Abstract][Full Text] [Related]
19. BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura.
Zhou Z; Chen Z; Li H; Chen X; Xu J; Gu D; Du W; Zheng C; Zhang L; Huang Y; Ren Q; Yang R
Autoimmunity; 2009 Feb; 42(2):112-9. PubMed ID: 19005881
[TBL] [Abstract][Full Text] [Related]
20. BAFF is elevated in serum of patients with Wegener's granulomatosis.
Krumbholz M; Specks U; Wick M; Kalled SL; Jenne D; Meinl E
J Autoimmun; 2005 Dec; 25(4):298-302. PubMed ID: 16242914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
